GLP-1 Medications, Muscle and Motivation: What the Research Actually Shows.

Sep 15

5 min read

Kamaldeep Sidhu MNIMH - Functional Health Practitioner and Health Coach

Last updated: 15.09.2026

More and more of the women I see and speak to in clinic, at the school gate and even in my own family - are taking a GLP-1 medication like Ozempic, Wegovy or Mounjaro. And more and more of them are asking me the same two questions: "Am I losing muscle, not just fat?" and "Why don't I feel like myself anymore?".

A woman shows focus as she lifts weights in a gym.

Both are good questions. Both deserve a proper answer, not a reassuring pat on the arm or a scare story from Instagram. So let's look at what the research actually says.

Will a GLP-1 medication make you lose muscle?

Yes, this is a real and well-documented risk, not a myth. Without any protective strategy, a meaningful share of the weight lost on these medications can come from lean mass rather than fat, and most of that lean mass is muscle [1].

That matters more than it sounds. Muscle isn't just about strength or appearance, it's your metabolic engine, your insulin sensitivity, your ability to carry your own shopping and get up off the floor at 75. Losing it alongside fat can leave you lighter on the scales but weaker and more metabolically fragile than before you started.

Why does this happen?

Here's where it gets more interesting, and more hopeful. A 2026 laboratory study looked directly at whether GLP-1 and GIP receptor agonists damage muscle cells directly, and found they don't appear to impair muscle regeneration or directly cause atrophy in human muscle cells [2]. The leading theory instead is that lean mass loss is largely a side effect of eating much less and moving the body less i.e. a calorie deficit and reduced mechanical loading rather than the drug attacking your muscle directly.

That distinction matters practically: if the muscle loss were a direct drug effect, there might be little you could do about it. If it's mostly a consequence of how you're losing weight, it's something you have real influence over.

What can you actually do about it?

The two levers that show up consistently in the research are the same two you'd expect from any weight-loss context, just more important here because appetite is so suppressed:

Protein, deliberately. Research on preserving lean mass during GLP-1 treatment points to a target above roughly 1.2g of protein per kg of body weight per day, spread across meals rather than loaded into one [3]. When you're simply not hungry, every meal has to work harder.
Resistance training, not just movement. Strength training gives your body a reason to keep the muscle you have, rather than let it go along with the fat.

Neither of these needs to be extreme. You don't need to hit the gym five days a week, it's about giving your body a clear signal, through food and through load-bearing movement, that muscle is still needed.

Does a GLP-1 medication kill your motivation?

This is the harder, murkier question and I would prefer to be honest about the uncertainty rather than pretend the research is settled.

There's a real, documented pattern worth taking seriously. A recent case series described three women on high-dose tirzepatide who reported reduced motivation, emotional flatness, and loss of interest in previously enjoyable activities, including exercise, despite the medication successfully helping them lose weight [4]. This kind of effect has picked up an informal name in the media, the "Ozempic personality" or "meh effect," though it isn't a formal diagnosis [5].

There's a plausible biological reason this could happen. These medications act on brain pathways involved in reward, not just appetite, and a systematic review found consistent effects on reward-related behaviour, largely framed as a positive, in that they seem to reduce food cravings and compulsive eating patterns, with researchers noting potential relevance to addiction treatment more broadly [6].

But - and this is the part that gets lost in the "Ozempic zombie" headlines - the wider evidence doesn't support the idea that these drugs typically flatten mood or motivation across the board. A large-scale review pooling dozens of randomised trials and well over 100,000 participants found these medications were, on average, associated with better mental health–related quality of life, not worse [7]. The UK's own medicines regulator has also reviewed this directly and did not find evidence of a causal link between GLP-1 medications and depression or self-harm [8].

So how do both things sit together? Timing is part of the answer. Sleep disruption, GI side effects, and feeling generally unwell can all independently affect mood and motivation, and because they often arrive around the same time as starting the medication, it can be hard to know what's actually driving what [8]. There's also a real biological argument that these drugs could improve motivation for some people - insulin resistance itself is linked to lower dopamine activity and anhedonia, so improving insulin sensitivity may restore some drive rather than blunt it [6].

So what does this actually mean for you?

If you're on one of these medications, or thinking about starting one, here's the grounded version, not the headline version:

Muscle loss is a real risk, but it's substantially within your control. Protein and resistance training are not optional extras here, they're the main lever you have. Changes in motivation or mood are worth paying attention to and never worth dismissing, but they're not inevitable, and if you notice them, it's worth mentioning to whoever is prescribing rather than assuming it's just "part of it" or something to push through alone.

Work with your biology, not against it. These medications can be a genuinely useful tool - but a tool works best alongside the things your body still needs: enough protein, a reason for your muscles to stay strong, and someone keeping an eye on how you're actually doing, not just what the scales say.

This is the first in a short series looking honestly at what the research says about GLP-1 medications - the good, the uncertain, and the bits nobody tells you.

References

Mechanick, Jeffrey I., W. Scott Butsch, Sandra M. Christensen, Osama Hamdy, Zhaoping Li, Carla M. Prado, and Steven B. Heymsfield. 2025. “Strategies for Minimizing Muscle Loss during Use of Incretin-Mimetic Drugs for Treatment of Obesity.” Obesity Reviews: An Official Journal of the International Association for the Study of Obesity 26 (1): e13841.
Ditchfield C, Macleod M, Price JMJ, Davis ET, Jones SW. "GLP-1 and GIP receptor agonism does not directly drive skeletal muscle atrophy or impair myogenesis in primary human myotubes." bioRxiv, 2026. https://www.biorxiv.org/content/10.64898/2026.07.20.739515.full.pdf
"Optimizing GLP-1 therapies for obesity and diabetes management" — protein target >1.2g/kg/day. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12661421/
"Resolution of anhedonia-like symptoms in patients treated for obesity with tirzepatide: A three-case series." PubMed. https://pubmed.ncbi.nlm.nih.gov/42518361/
Pierret ACS, Mizuno Y, Saunders P, Lim E, De Giorgi R, Howes OD, McCutcheon RA, McGowan B, Sen Gupta P, Smith D, Ismail K, Pillinger T. Glucagon-Like Peptide 1 Receptor Agonists and Mental Health: A Systematic Review and Meta-Analysis. JAMA Psychiatry. 2025 Jul 1;82(7):643-653. doi: 10.1001/jamapsychiatry.2025.0679. PMID: 40366681; PMCID: PMC12079569..
"Glucagon-like peptide 1 agonist and effects on reward behaviour: A systematic review." PubMed / ScienceDirect. https://pubmed.ncbi.nlm.nih.gov/38945189/
Pierret ACS, Mizuno Y, Saunders P, Lim E, De Giorgi R, Howes OD, McCutcheon RA, McGowan B, Sen Gupta P, Smith D, Ismail K, Pillinger T. Glucagon-Like Peptide 1 Receptor Agonists and Mental Health: A Systematic Review and Meta-Analysis. JAMA Psychiatry. 2025 Jul 1;82(7):643-653. doi: 10.1001/jamapsychiatry.2025.0679. PMID: 40366681; PMCID: PMC12079569..
Medicines and Healthcare products Regulatory Agency (MHRA). "MHRA finds evidence does not support a link between Glucagon-Like Peptide-1 (GLP-1) receptor agonists and suicidal and self-injurious thoughts and actions." GOV.UK, 4 September 2024. https://www.gov.uk/government/news/mhra-finds-evidence-does-not-support-a-link-between-glucagon-like-peptide-1-glp-1-receptor-agonists-and-suicidal-and-self-injurious-thoughts-and-act